Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22737771 | 0.84 | KMT2A (0.57) | MAPTHPGDGAANPSR1KMT2A | |
| SCHEMBL22737561 | 0.82 | GBA1 (0.49) | MAPTGAANPSR1PAX8KMT2A | |
| SCHEMBL13944049 | 0.78 | MAPT (0.60) | MAPTHPGDGAANPSR1KMT2A | |
| SCHEMBL15890518 | 0.77 | MTOR (0.65) | MAPTHPGDGAANPSR1KMT2A | |
| SCHEMBL8239323 | 0.77 | MAPT (0.51) | MAPTGAANPSR1KMT2ASMN1; SMN2 | |
| SCHEMBL13943387 | 0.76 | MAPT (0.60) | MAPTHPGDGAANPSR1KMT2A | |
| SCHEMBL19016813 | 0.75 | MAPT (0.61) | MAPTGAAKMT2ASMN1; SMN2LMNA | |
| SCHEMBL12685994 | 0.74 | MAPT (0.71) | MAPTGAANPSR1KMT2ASMN1; SMN2 | |
| SCHEMBL22737390 | 0.73 | GBA1 (0.47) | MAPTGAANPSR1PAX8KMT2A | |
| SCHEMBL3327945 | 0.73 | MTOR (0.60) | MAPTHPGDGAANPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200375996-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | D.E. SHAW RESEARCH, LLC (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375996-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, NEDD4 | MAPT 48/4885HPGD 3896/4885GAA 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.